ALC.SW Alcon Inc. (SIX) 20 Jan 2026: CHF62.54 close, high volume highlights outlook
ALC.SW stock closed at CHF 62.54 on 20 Jan 2026 as markets in Switzerland ended the session. Volume was 1,091,261 shares versus an average of 1,158,099, marking Alcon among the most active SIX names today. The move added CHF 1.36 or 2.22% to the price, with a day range CHF 61.52–62.76. Traders flagged the gap to the 200‑day average CHF 67.04 and the upcoming earnings date of 24 Feb 2026 as drivers for near‑term positioning.
ALC.SW stock intraday snapshot and trading volume
Alcon Inc. (ALC.SW) finished the market closed session on SIX at CHF 62.54. Today’s volume 1,091,261 was near the 30‑day average, keeping the stock in the exchange’s most active list.
The intraday range CHF 61.52–62.76 shows intra‑day support around CHF 61.50 and short‑term resistance near CHF 63.72, the middle Bollinger band. The stock remains 9.46% below its 52‑week high CHF 87.00 and 8.42% above its 52‑week low CHF 57.68.
Key drivers: earnings, product mix and sector trends
Investors focused on the upcoming earnings announcement on 24 Feb 2026 and Alcon’s surgical and vision care sales cadence. Consensus risk stems from surgical procedure volumes and contact lens demand. Healthcare sector momentum has outperformed recently; the Swiss Healthcare sector average P/E is 33.69, while Alcon trades at PE 37.23, indicating a modest premium.
Product launches and the AcrySof IOL franchise remain core revenue drivers. Alcon reported steady operating cash flow growth and a strong free cash flow yield 4.19% on a TTM basis, which supports the payout and capital spending programmes.
Fundamentals and valuation snapshot for ALC.SW stock
Alcon shows conservative leverage with debt/equity 0.24 and a current ratio 2.12, signalling liquidity strength. Key TTM metrics include EPS 1.68, PE 37.23, Price/Book 1.71, and EV/EBITDA 20.30. Free cash flow per share stands at CHF 3.22 and dividend per share at CHF 0.35.
On growth, FY 2024 revenue rose 4.82% and operating cash flow grew 49.64% year over year. These metrics underpin a measured premium to the healthcare group and help explain why investors trade ALC.SW stock among active Swiss healthcare names.
Technical picture: support, resistance and indicators
Technicals show a neutral to mildly bullish setup. RSI is 58.62, MACD 0.49 with signal 0.46, and ADX 14.16 indicating no strong trend. The 50‑day average is CHF 63.01, and the 200‑day average is CHF 67.04. Bollinger bands sit Upper 65.20 / Middle 63.72 / Lower 62.24.
Short‑term momentum favors buyers above CHF 62.24. Failure to hold CHF 61.50 could open a decline toward the 50‑day average. Volume interest and a positive MACD histogram support a tactical long bias for active traders.
Meyka AI grade and analyst outlook for ALC.SW
Meyka AI rates ALC.SW with a score out of 100: 71.87 — Grade B+ (BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
The company rating from market data shows a B / Neutral composite, but Meyka’s model skews to BUY due to cash flow strength and recent operational improvements. Remember, grades are model outputs and not personalized financial advice.
Risks and opportunities for active traders
Risks include slower surgical procedure volumes, currency swings, and margin pressure from R&D spend. Valuation sensitivity is evident: P/E above sector peers increases downside risk if growth stalls.
Opportunities are driven by product upgrades, FCF improvement, and recovery in elective procedures. Active traders should watch the earnings release on 24 Feb 2026, the CHF 67.04 200‑day average, and short‑term volume spikes for trade confirmation.
Final Thoughts
Key takeaways on ALC.SW stock: Alcon closed CHF 62.54 on 20 Jan 2026 after active trade of 1,091,261 shares. Fundamentals show liquidity and cash flow strength, but valuation sits above the Swiss healthcare average at PE 37.23. Technicals are neutral‑to‑bullish with RSI 58.62 and the 200‑day average at CHF 67.04. Meyka AI’s forecast model projects a near‑term monthly target CHF 69.13, implying an upside of 10.54% versus today’s price. A conservative 12‑month base target of CHF 67.00 implies +7.13%, while a bull target of CHF 75.00 implies +19.91%. Forecasts are model‑based projections and not guarantees. Active traders should monitor the 24 Feb 2026 earnings release, volume trends, and whether the stock closes above the CHF 63.72 mid‑band to confirm further strength. For a deeper data view visit our Meyka AI stock page and Alcon investor site for company filings and updates Meyka ALC.SW Alcon investors Reuters profile.
FAQs
What drove ALC.SW stock higher on 20 Jan 2026?
ALC.SW stock rose 2.22% to CHF 62.54 on 20 Jan 2026 driven by above‑average volume, positive technical momentum and positioning ahead of earnings on 24 Feb 2026.
What is Meyka AI’s short‑term forecast for ALC.SW stock?
Meyka AI’s forecast model projects a monthly target of CHF 69.13, implying an upside of 10.54% from the current price CHF 62.54. Forecasts are model‑based projections and not guarantees.
How is Alcon valued versus its sector?
Alcon trades at PE 37.23, above the Swiss healthcare average PE 33.69. Price/Book is 1.71 and free cash flow yield is 4.19%, indicating premium valuation supported by cash generation.
What key levels should traders watch for ALC.SW stock?
Watch intraday support CHF 61.50, the Bollinger middle CHF 63.72, and the 200‑day average CHF 67.04. A close above CHF 63.72 would favor buyers.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
